Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2023
Event: Entry into a Material Definitive Agreement (Contingent Convertible Debt Agreement).
Key Financial Metrics and Debt Structure
- New Debt Principal: $16.56 million aggregate original principal amount.
- Refinanced Debt: Replaced a prior $15.0 million contingent convertible term loan (satisfied in full).
- Interest Rate: Floating rate (greater of 2.25% or Prime minus 1.0%) payable in cash monthly, plus 7.0% per annum compounded monthly payable at maturity or conversion.
- Maturity Date: December 22, 2024 (subject to acceleration based on FDA New Drug Application filing status).
- Collateral: Secured by substantially all assets except intellectual property.
- Conversion Price: $9.34 per share (subject to adjustments).
- Automatic Conversion Trigger: Occurs if the closing stock price is $\ge$ $24.00 for 30 consecutive trading days and liquidity conditions are met.
Material Changes Versus Prior Period
The company refinanced its existing $15.0 million debt obligation from December 2021 with a new $16.56 million facility. This represents an increase in principal of $1.56 million. The new agreement terminates the prior debt agreement entirely. The maturity date has been extended to late 2024, contingent upon regulatory milestones regarding the company's New Drug Application (NDA) for cytisinicline.
Guidance, Risks, and Unusual Items
- Regulatory Milestones: The maturity date accelerates to August 2024 if the FDA does not accept the NDA for filing by July 31, 2024, or if material deficiencies are noted in the filing communication by August 14, 2024.
- Call Right (Prepayment): The company may repay the loan early but faces significant penalties: 125% of principal if repaid by June 22, 2023, and 150% thereafter. Prepayment is restricted if "Liquidity Conditions" are not satisfied.
- Acquisition Penalty: If the company repays the loan and consummates an acquisition within 12 months, it must pay the difference between the actual repayment and the proceeds the lenders would have received had they converted the debt.
- Ownership Caps: Conversion is limited to prevent any holder from beneficially owning more than 9.99% (or 19.99% for Section 16 officers/directors) of outstanding common stock.
- Covenants: Includes restrictions on additional indebtedness, liens, dividends, and distributions. Lenders are prohibited from short selling or hedging the company's stock.
- Registration Rights: The company must register shares issuable upon conversion within 30 days, subject to a 7% ownership threshold exception.
Investor Verification Checklist
- Verify the current status of the New Drug Application (NDA) for cytisinicline to assess the risk of maturity date acceleration.
- Confirm the company's current cash position to evaluate its ability to meet monthly cash interest payments and potential prepayment penalties.
- Review the "Liquidity Conditions" defined in the Debt Agreement to understand restrictions on early repayment.
- Monitor the stock price relative to the $24.00 automatic conversion trigger and the $9.34 conversion price.
- Check for any pending acquisitions that could trigger the additional call price provision.